NovoCure Debt to Equity Ratio 2014-2023 | NVCR
Current and historical debt to equity ratio values for NovoCure (NVCR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. NovoCure debt/equity for the three months ending December 31, 2023 was 1.57.
| NovoCure Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $0.78B | $0.36B | 2.16 |
| 2023-09-30 | $0.75B | $0.39B | 1.91 |
| 2023-06-30 | $0.74B | $0.42B | 1.79 |
| 2023-03-31 | $0.74B | $0.43B | 1.72 |
| 2022-12-31 | $0.75B | $0.44B | 1.70 |
| 2022-09-30 | $0.73B | $0.45B | 1.64 |
| 2022-06-30 | $0.72B | $0.44B | 1.63 |
| 2022-03-31 | $0.71B | $0.44B | 1.64 |
| 2021-12-31 | $0.73B | $0.41B | 1.78 |
| 2021-09-30 | $0.71B | $0.41B | 1.71 |
| 2021-06-30 | $0.70B | $0.40B | 1.76 |
| 2021-03-31 | $0.70B | $0.37B | 1.87 |
| 2020-12-31 | $0.58B | $0.48B | 1.21 |
| 2020-09-30 | $0.12B | $0.31B | 0.40 |
| 2020-06-30 | $0.26B | $0.27B | 0.98 |
| 2020-03-31 | $0.26B | $0.24B | 1.08 |
| 2019-12-31 | $0.26B | $0.22B | 1.20 |
| 2019-09-30 | $0.25B | $0.19B | 1.33 |
| 2019-06-30 | $0.25B | $0.16B | 1.56 |
| 2019-03-31 | $0.24B | $0.13B | 1.93 |
| 2018-12-31 | $0.23B | $0.11B | 2.03 |
| 2018-09-30 | $0.20B | $0.12B | 1.75 |
| 2018-06-30 | $0.20B | $0.11B | 1.77 |
| 2018-03-31 | $0.20B | $0.11B | 1.86 |
| 2017-12-31 | $0.15B | $0.11B | 1.34 |
| 2017-09-30 | $0.15B | $0.12B | 1.25 |
| 2017-06-30 | $0.14B | $0.12B | 1.19 |
| 2017-03-31 | $0.14B | $0.13B | 1.05 |
| 2016-12-31 | $0.14B | $0.14B | 0.98 |
| 2016-09-30 | $0.13B | $0.16B | 0.84 |
| 2016-06-30 | $0.06B | $0.19B | 0.34 |
| 2016-03-31 | $0.06B | $0.22B | 0.27 |
| 2015-12-31 | $0.06B | $0.25B | 0.23 |
| 2015-09-30 | $0.05B | $0.12B | 0.43 |
| 2015-06-30 | $0.05B | $0.14B | 0.34 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.00B | 0.00 | |
| 2014-09-30 | $0.00B | $0.00B | 0.00 |
| 2013-12-31 | $0.02B | $0.17B | 0.10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.297B | $0.509B |
| NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $123.860B | 15.54 |
| Cencora (COR) | United States | $47.415B | 18.92 |
| ICON (ICLR) | Ireland | $25.281B | 24.93 |
| DiDi Global (DIDIY) | China | $23.464B | 0.00 |
| Avantor (AVTR) | United States | $17.398B | 23.97 |
| CochLear (CHEOY) | $13.726B | 0.00 | |
| Viatris (VTRS) | United States | $13.628B | 3.89 |
| Revvity (RVTY) | United States | $12.785B | 22.26 |
| Medpace Holdings (MEDP) | United States | $12.615B | 41.50 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.511B | 0.00 |
| Charles River Laboratories (CRL) | United States | $12.369B | 22.55 |
| Natera (NTRA) | United States | $10.994B | 0.00 |
| Solventum (SOLV) | United States | $10.955B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
| HealthEquity (HQY) | United States | $6.853B | 51.20 |
| Bausch + Lomb (BLCO) | Canada | $5.218B | 20.07 |
| Organon (OGN) | United States | $4.734B | 4.58 |
| Doximity (DOCS) | United States | $4.585B | 34.14 |
| PACS (PACS) | United States | $3.659B | 0.00 |
| Sotera Health (SHC) | United States | $3.221B | 15.81 |
| Surgery Partners (SGRY) | United States | $3.213B | 29.86 |
| Progyny (PGNY) | United States | $3.114B | 52.26 |
| Life Times (LTH) | United States | $2.882B | 31.85 |
| GoodRx Holdings (GDRX) | United States | $2.753B | 139.40 |
| Premier (PINC) | United States | $2.520B | 9.22 |
| Teladoc Health (TDOC) | United States | $2.326B | 0.00 |
| Agilon Health (AGL) | United States | $2.195B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.166B | 7.01 |
| BrightSpring Health Services (BTSG) | United States | $1.832B | 0.00 |
| Agiliti (AGTI) | United States | $1.366B | 22.31 |
| Establishment Labs Holdings (ESTA) | $1.364B | 0.00 | |
| Alignment Healthcare (ALHC) | United States | $0.979B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.790B | 8.17 |
| Embecta (EMBC) | United States | $0.626B | 4.14 |
| InnovAge Holding (INNV) | United States | $0.544B | 0.00 |
| Enhabit (EHAB) | United States | $0.515B | 46.68 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.511B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.506B | 0.00 |
| LifeMD (LFMD) | United States | $0.440B | 0.00 |
| CareDx (CDNA) | United States | $0.426B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.419B | 0.00 |
| Beauty Health (SKIN) | United States | $0.397B | 0.00 |
| DocGo (DCGO) | United States | $0.365B | 58.33 |
| MultiPlan (MPLN) | United States | $0.361B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.323B | 0.00 |
| ModivCare (MODV) | United States | $0.320B | 4.24 |
| GeneDx Holdings (WGS) | United States | $0.313B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.285B | 0.00 |
| Sharecare (SHCR) | United States | $0.262B | 0.00 |
| Biodesix (BDSX) | United States | $0.124B | 0.00 |
| So-Young (SY) | China | $0.123B | 41.33 |
| Oncology Institute (TOI) | United States | $0.088B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.075B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
| NeueHealth (NEUE) | United States | $0.051B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
| Nutex Health (NUTX) | United States | $0.033B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.031B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.027B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.020B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.015B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.013B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.010B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.009B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| OpGen (OPGN) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Assure Holdings (IONM) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |